Johnson & Johnson (J&J) recently announced the US launch of the Cereglide 42 and Cereglide 57 aspiration catheters—along with the Innerglide 7 delivery aid—making them the latest additions to its aspiration-first stroke care portfolio.
According to the company, these devices “complete” the Cereglide family, and are designed to help physicians reach and remove distally located clots more consistently while simplifying procedural decisions and supporting performance across a broad range of ischaemic stroke cases.
“We designed this multi-axial system to address procedural challenges physicians face when treating stroke,” said Christian Cuzick, worldwide president of neurovascular at J&J MedTech. “With this expanded portfolio, we’re simplifying decisions, enhancing consistency across device sizes, and reinforcing our commitment to helping improve patient outcomes.”
Cereglide 42 and Cereglide 57 are built with a proprietary, variable-stiffness construction that provides flexible distal navigation and supportive proximal control. Additionally, J&J states that both catheters are intended to integrate “seamlessly” into existing neurointerventional workflows, offering: hydrophilic coating for reduced friction in tortuous anatomy; a radiopaque—based on benchmark testing—tip marker for fluoroscopic visibility; and easy trackability to the M2 segment of the middle cerebral artery (MCA) with TruCourse technology.
“Accessing distal occlusions remains one of the biggest technical challenges we face, especially in smaller or more tortuous vessels,” commented Ameer Hassan (Valley Baptist Medical Center, Harlingen, USA). “In my experience, Cereglide 42 and 57 track reliably while maintaining strong proximal support, even over multiple passes. That balance of flexibility and control gives me greater confidence when performing aspiration-first thrombectomy in more complex anatomy.”
Innerglide 7 is a delivery aid designed to support the advancement of large-bore catheters like Cereglide 71 to distal clot locations. It features a hydrophilic-coated shaft, 1.5cm soft distal tip, and compatibility with 0.024-inch guidewires, offering added control and support during complex device delivery.
“Reaching the M2 segment with large-bore aspiration systems can be technically demanding,” Hassan added. “Innerglide 7 provides the additional support needed to consistently deliver Cereglide 71 into more distal targets with smoother navigation and less resistance. I am a firm believer in delivery catheter technology like Innerglide.”
